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Health Risks and Emerging Trends
with the Use of Electronic Cigarettes
Lucy Wagala, Austin Hopkins, Natalie Lennartz, Brian Heilbronner, Brittany L. Long, PharmD,
Natalie DiPietro Mager, PharmD, MPH
Abstract
Cigarette smoking is associated with many health risks and
complications. Despite smokers' strong desire to quit, most
battle with nicotine withdrawal and relapse. Because electronic cigarettes Ce-cigarettes) do not contain tobacco, some
believe them to be safer than traditional cigarettes and have
used them as a replacement or adjunct nicotine source to
prevent withdrawal symptoms. Electronic cigarettes are designed to mimic traditional cigarettes and expel a vapor
composed of nicotine, water, glycerol, propylene glycol and
other flavorings. Many e-cigarette companies use appealing
platforms, which promise smoking cessation and harm
reduction, to attract consumers; however, several studies
have found e-cigarettes actually contain ingredients that are
harmful to one's health. Studies have demonstrated that the
use of e-cigarettes can be toxic to patients' health if patients
do not research the products they intend to purchase. The
flavoring of e-cigarettes may be a major contributor to
e-cigarette cytotoxicity. If flavoring and other cytotoxic contents of e-cigarettes can be eliminated, e-cigarettes may be
useful in smoking reduction and cessation. Many clinicians
today support traditional forms of nicotine replacement therapy for smoking cessation rather than e-cigarettes. Due to
the lack of regulation and studies by the U.S. Food and Drug
Administration, e-cigarettes may not be as safe as users may
perceive and should not be a preferred product for smoking
cessation therapy until they are further studied and regulated.
Key Terms

Electronic Cigarettes; Nicotine; Pharmacies; Safety; Smoking
Cessation

smoker but also to the people around the smoker. Additionally, second-hand smoke harms the atmosphere by degrading
air quality and significantly contributes to littering, where
cigarette butts are listed as the most littered item. It is also
extremely costly to clean up littering related to smoking.s For
example, in places like San Francisco, it costs up to $10.7 million to remove cigarette butts from public spaces each year.
The production of cigarettes alone is also detrimental to the
environment, as for every 300 cigarettes that are produced,
one tree is consumed.s.6 Improper discarding of cigarettes
has been found to cause destructive wildfires which leads to
damaged properties, vegetation, forestry, animal habitats
and death.6
Smoking cessation can help decrease the risk of smokingrelated diseases and add years to past-smokers' lives.7 According to a survey by the Centers for Disease Control and
Prevention (CDC) in 2010, almost 70 percent of adult smokers said they wanted to quit smoking completely. Smokers in
the beginning stages of quitting often experience severe
withdrawal symptoms due to nicotine addiction.a Nicotine,
the primary psychoactive chemical in tobacco, is highly addictive, and smokers who quit often experience intense withdrawal symptoms including extreme nicotine cravings, depression, anxiety, difficulty sleeping, nightmares, headaches,
increased appetite and weight gain.9 Medications containing
nicotine such as lozenges, gums and patches can help to decrease the withdrawal symptoms and cigarette cravings,
when used correctly, and could potentially double a smoker's
chances of quitting.a Some people have turned to e-cigarettes
as a nicotine replacement or adjunct therapy option for
smoking cessation.10 Electronic cigarettes provide patients
with the sensation of smoking; however, what most people
do not know is that e-cigarettes have not been proven safe or
effective in smoking cessation.

Introduction
Cigarette smoking is linked to multiple, serious health risks.
Smoking impairs almost every organ in the body, causes several diseases, increases healthcare costs and negatively impacts the overall health of people who choose to use these
products. 1 While only 18 percent of the U.S. population were
smokers in 2012 compared to 42 percent in 1965, there are
still about 42 million Americans who continue to smoke.2 In
2012, about 21 percent of all American men and about 16
percent of all American women smoked. Furthermore, smoking is a problem among adolescents, and it is estimated that
each day more than 3,200 teenagers smoke for the first
time.3 This results in nearly 14 percent of high school students and 4 percent of middle school students being considered as current cigarette smokers.

Hon Lik, a pharmacist and smoker in China, developed
e-cigarettes in 2003 after his father died of lung cancer.11
Electronic cigarettes were later introduced to the United
States in late 2006 and early 2007. However, e-cigarettes did
not become popular until 2013 when a number of large
tobacco companies invested in their production.12 As a twopacks-per-day smoker, Hon Lik developed e-cigarettes in
hopes of producing a method that would help himself quit. In
the past he had tried nicotine patches, but they failed to give
him the "rush" associated with smoking cigarettes he
enjoyed. Thus, e-cigarettes were designed to imitate "smoke
without fire."13

Smoking not only impacts a person's health but also affects
the public environment. 4 Smoke contains carcinogens, toxic
metals and poisonous gases that are harmful to not only the

Electronic cigarettes vaporize a mixture of liquid nicotine,
water, glycerol, propylene glycol and other flavorings.12 They
consist of an atomizer, which heats the liquids into a vapor; a
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cartridge, which holds the e-Iiquids; and a rechargeable battery, which powers the atomizer. Electronic cigarettes contain no tobacco, odor or smoke. Most are designed to be used
and appear as a cigarette so that when a user draws on it,
visible vapor is produced while a light-emitting diode (LED)
portrays a real cigarette glow. Aside from the traditional tobacco and menthol flavors, more than 200 other
flavors, such as bubblegum and cherry, exist. Before using an
e-cigarette, the user must first attach the cartridge. 14 Most
e-cigarettes are activated when a user inhales, causing the
atomizer to heat the liquid and turn it into a vapor, while
other e-cigarettes are activated with a switch. Inhalation of
the vapor through the mouthpiece delivers nicotine to the
user's lungs and, upon exhalation, gives an appearance similar to a cloud of smoke.

Emerging Trends
Electronic cigarette use has risen rapidly over the last few
years. The number of adults in the United States who used an
e-cigarette rose from 3.3 percent in 2010 to 8.5 percent in
2013, and the number of current cigarette smokers who have
used e-cigarettes has risen from 9.8 percent to 36.5 percent.15 From 2013 to 2014, the number of high school students who used an e-cigarette in the past month tripled to
13.4 percent, and the number of high school students that
have never used cigarettes, but have used e-cigarettes, increased to an estimated 250,000. 16 Marketing of e-cigarettes
by tobacco companies is extensively aimed at youth under
the age of 21 years, specifically high school students, where
companies invest in advertising their products through magazines, movies, sponsorship of concerts and auto races, and
celebrity endorsements and researching youth behaviors to
generate attracting themes.16-10
Currently, only e-cigarettes marketed for therapeutic purposes are regulated by the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research
(CDER).19 Other tobacco products, such as cigarettes, smokeless tobacco and roll-your-own tobacco are currently regulated by the FDA Center of Tobacco Products (CTP). However,
to address the public issue of unhealthy tobacco use, a rule
named "Tobacco Products Deemed To Be Subject to the Food,
Drug & Cosmetic Act" has been proposed by the FDA to expand its authority to regulate all products that are considered tobacco products, including e-cigarettes.20 State and
local governments also have laws about tobacco products,
which include prohibiting smoking and tobacco in public
places, taxing tobacco products, enforcing Medicaid to cover
smoking cessation programs and prohibiting the sale of
flavored tobacco products.21 In 2006, Ohio instituted a
statewide ban against tobacco requiring businesses and
organizations to prohibit smoking.22

Electronic Cigarettes: Cytotoxicity and Other Health
Risks
While e-cigarettes are becoming a popular alternative to tobacco cigarettes, many health professionals are wary in recommending these products to their patients primarily because e-cigarettes have not been proven safe for long-term
use. 23 Common complaints from e-cigarette users are headWinter 2016 Volume
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ache, respiratory tract infection and changes in appetite. Upon initial investigation of e-cigarettes, they may appear to be
a good alternative to traditional cigarettes. Most e-cigarette
companies use the appealing platform of promising smoking
cessation and harm reduction to attract consumers.However, without knowing the long-term health risks associated
with e-cigarettes, it can be difficult for a healthcare professional to provide any recommendation of e-cigarettes to both
tobacco and non-tobacco users.24
Farsalinos and colleagues performed a study to determine
whether or not e-cigarettes are less harmful than tobacco
cigarettes_ 25 They measured and compared the cytotoxic potential of cigarette smoke and e-cigarette vapor extract on
cultured myocardial cells. Additionally, they measured
whether or not using a higher voltage (3.7 volts versus 4.7
volts) has an effect on cytotoxicity of e-cigarette agents. Electronic cigarette and cigarette smoke samples were tested in
vapor form, as this is the form most used by consumers. Cytotoxicity was defined as viability less than 70 percent based
on a specific protocol (ISO 10993-5). This was only done on
low voltage e-cigarette samples due to an insufficient number of high voltage samples to demonstrate a significant difference.
The authors tested the vapor cytotoxicity of one cigarette
smoke sample, 20 e-cigarette liquid samples and an
e-cigarette base sample at five different concentrations: 100
percent, 50 percent, 25 percent, 12.5 percent and 6.25 percent.25 Table 1 demonstrates the myocardial cell viability at
low voltage of the cigarette smoke sample, base sample and
the four e-cigarette vapor extracts that demonstrated a cytotoxic effect. Most tobacco producing samples exhibited the
lowest survival rates. The base sample, containing 50 percent
propylene glycol, 50 percent glycerol and no nicotine or flavoring, was considered non-cytotoxic at any extract concentration. Cigarette smoke was significantly more cytotoxic
than e-cigarette samples with cytotoxicity exhibited at all
concentrations above 6.25 percent. The most cytotoxic of the
four samples was "El Toro Puros." Results of high voltage
samples above 6.25 percent were not considered statistically
significant due to the small amount of samples tested. The
authors admitted the need to perform further studies, using
more samples and more efficient atomizers, to determine the
viability of e-cigarette use in higher voltage samples. Farsalinos and colleagues also suggested that flavoring, and the
varying quantities of flavorings in liquids, may be a major
contributor to e-cigarette cytotoxicity. Some flavorings are
approved for use in food, but their effects when heated or
evaporated are unknown.
A study by Romagna and colleagues also suggested flavoring
as a cause of cytotoxicity in e-cigarettes liquid.26 In the study,
21 e-cigarette liquids were tested, and only one out of the 21
liquids had cytotoxic properties when exposed to cultured
mammalian fibroblasts. All samples were produced by the
same manufacturer and had the same main ingredients
(propylene glycol, glycerol and nicotine) in similar concentrations, leaving flavoring as the only contributor to varying
cell viability.
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Table 1. Myocardial Cell Viability in Cigarette Smoke and Electronic Cigarette Vapor Extracts at 3.7 volts (low
voltage ). 25
Dilutions
Samples

100%

50%1

25%

12.500/ri

6.25%

Cinnamon-Cookies

64.8± 2.5%

100.8±2.0%

97.2± 2.9%

99.3± 1.7%

99.2± 3.8%

El Toro Cigarillos-1

39.1±1.2%

52.5±1.8%

81.0± 2.0%

92.6± 0.4%

99.2± l.0%

El Toro CigarilJos-Z

22.3±4.0%

66.9± 6.2%

104.1± 5.8%

109.9±6.0%

112.0± 8.8%

El Toro Puros

2.2± 0.6%1

7.4± 3.9%

84.5±6.5%

115.3± l l.7%

111.9±7..lo/o

Base Sample

105.1± 1.2%

103.5± 1.9%

101.3± 4.2%

100.7± 3.4%

100.4± 2.3%

Cigarette smoke

3.9± 0.2%1

5.2 ± 0.8 1%

3.1± 0.2%

38.2± 0.6%

76.l) ± 2.0%

Data comparing cytotoxicity between e-cigarettes and cigarette smoke was reported using mean± standard deviation. Data
comparing e-cigarette samples was reported using a paired t-test. Among e-cigarette samples, an independent t-test was
used to assess whether nicotine levels played a role in viability. A two tailed p value< 0.05 was considered statistically significant. All samples, besides the base, had p values <0.001 and were considered statistically significant.

Studies evaluating the cytotoxicity of individual flavors in
vapor form and the cytotoxicity of flavors at different
concentrations may be essential in the production of safe
e-cigarettes.21 Bahl and colleagues completed a study using
embryonic and adult cells to compare the cytotoxicity of various e-cigarette refill fluid flavors. They used three cell types:
cells modeling the epiblast stage of human embryonic development (hESC), mouse neural stem cells (mNSC) isolated
from the brain of a newborn and human pulmonary fibroblasts (hPF) representing adult cells from one of the initial
points of contact of inhaled e-cigarette aerosol. Thirty-four
refill fluid samples of varying doses, flavorings and nicotine
concentrations were compared in all cell types, and found to
differ significantly in potency. Refill fluids used were obtained from popular companies whose products are easily
accessible to e-cigarette users online. Ninety-six well plates
were filled with negative controls and refill solutions of various doses (0.001%, 0.01%, 0.03%, 0.1%, 0.3% and 1%). Table 2 shows the half maximal inhibitory concentration (!Cso)
of the refill fluid product flavors that produced the most significant results and are the most common humectants used
in refill fluid . Vegetable glycerin (VG) and propylene glycol
(PG) are the two humectants most often used in refill solutions, and these were considered non-cytotoxic for both cell
types. Menthol Artie (Freedom Smoke USA) and Caramel #40
(Global Smoke) demonstrated the strongest cytotoxic effects
on hPF cells. Cinnamon Ceylon was found to be the most potent sample and the only one that produced strong cytotoxic
effects on all three types of cells. The Bubblegum sample was
tested and found to be non-cytotoxic. The authors warned
that the cytotoxicity results achieved were potentially inaccurate. This is because the study used doses of vapor that
were 100 times lower than the actual doses consumers
would use. Therefore, a flavor demonstrating no toxicity at a
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1 percent concentration, which was used in this study, may
actually exhibit cytotoxicity when consumed at normal high
doses such as 10 percent.
The study then used high pressure liquid chromatography
spectra and found that products of the same flavor varied in
flavor peaks and cytotoxicity.27 For example, Butterscotch
#30 and Butterscotch #29 had low toxicity and had fewer
and shorter flavoring peaks (low chemical concentrations).
In contrast, Butterscotch #20, which demonstrated cytotoxicity, had greater and higher flavor peaks (high chemical concentrations). These results demonstrate that companies are
not always consistent with the contents of their products.
Products of the same flavor from one manufacturer can vary
in the amount of chemicals and, therefore, the levels of cytotoxicity. Additionally, stem cells from embryos and newborns
were found to be more sensitive to refill solution than differentiated adult lung cells; consequently, it will be essential in
future studies for e-cigarette cytotoxicity to be tested during
pregnancy and in multiple cell types.
This study also examined the effects of nicotine on the cytotoxicity of e-cigarettes.27 In Table 2, the nicotine levels of the
refill fluids and humectants are shown. Samples containing
nicotine concentrations ranging from 0 to 24 mg/mL were
used. Propylene glycol, VG, Caramel #26, Butterscotch #30,
Menthol Artie, Butterscotch #20, Cinnamon Ceylon and Caramel #21 contained 0 mg nicotine/mL; however, they differed
in cytotoxicity. Propylene glycol, VG, Caramel #26, Butterscotch #30 and Menthol Artie were non-cytotoxic/low cytotoxicity while Butterscotch #20, Cinnamon Ceylon and Caramel #21 were considered toxic. Bubblegum and Butterfinger
#19 were considered to have no cytotoxicity or low cytotoxicity but contained 24 mg nicotine/ml.
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This study demonstrates that in order to truly confirm the
cytotoxicity of e-cigarettes additional studies will need to be
completed with great caution.27 As this study only examined
the end result of exposure, studies evaluating the reason for
differences in cell survival may be beneficial. The results also
demonstrate that high levels of nicotine do not correlate with
high cytotoxicity in e-cigarettes, leaving the flavoring of
e-cigarettes as the main cause of e-cigarette toxicity.

Public Health

stances include carbonyl compounds, volatile organic compounds, nitrosamines, ultrafine particulate matter and heavy
metals. Performing studies on the cytotoxicity of these additional agents is important because they are known to contribute to various disease processes. Even the humectant
propylene glycol, which is not cytotoxic in liquid form, has
been found to contribute to allergic respiratory symptoms,
and the safety of inhaling its vaporized form has not been
tested in humans. By eliminating their cytotoxic flavors and
other cytotoxic component, e-cigarettes may be able to contribute safely to tobacco reduction and cessation.

Aside from flavoring, there are several other toxic substances
present in e-cigarette cartridges at low levels.2s These sub-

. Leve san dN'1cotme content o fV arious
.
Re fllFl
I
UI"dP ro d uct Fl avors. 27
Ta bl e 2 c;ytotox1c
Refill fluid (Company)

Cell Type

Nicotine (mg/ml)
hESCc

mNSCtl

hPFe

Propylene glycol (FS-USA)a

Low

Low

Low

Vegetable Glycerin (FS·USA)

Low

Low

Low

Bubblegum #18 (FS-USA)

24

Low

Low

Low

Butterscotch #30 (FS-USA)

0

Low

Low

Low

Butterscotch #29 (FS-USA)

6

Low

Low

Low

Caramel #26 (Freedom Smoke)

0

Low

Low

Low

Caramel #27 (Freedom Smoke)

6

Low

Low

Low

Caramel #28 (Freedom Smoke)

6

Low

Low

Low

Caramel #40 (Global Smoke)

18

Moderate

Low

Moderate

Butterfinger #19 (FS·USA)

24

Moderate

Low

Low

Menthol Arctic (Freedom Smoke)

0

Moderate

Low

Moderate

Vanilla Tahity (FS·USA)

0

Moderate

Moderate

Moderate

Pure nicotine (FS-USA)

100

Moderate

Moderate

Moderate

Caramel #21 (Freedom Smoke)

0

Moderate

Moderate

Moderate

Arctic Menthol (Johnson Creek)

18

High

Moderate

Low

Butterscotch #20 (FS·USA)

0

High

Moderate

Moderate

Cinnamon Ceylon (FS·USA)

0

High

High

High

Butterscotch #41 (Freedom Smoke)h

0

---

Moderate

Moderate

Refill products were considered to be non-cytotoxic or have low cytotoxicity if ICso>l %, moderate toxicity if IC 50 was 0.1·1 %,
and high cytotoxicity if ICS0<0.1 %.
afreedom Smoke USA
h8utterscotch #41 was only tested in mNSC and hPF because it was ordered and arrived from the manufacturer later in the
experiment.
c(e!ls modeling the epiblast stage of human embryonic development
dMouse neural stem cells isolated from the brain of a newborn
•Human pulmonary fibroblasts
Winter 2016 Volume 7, Issue 1
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Electronic Cigarettes: Examining Utility for Smoking
Cessation Therapy
In a prospective proof of concept six-month pilot study, Polosa and colleagues examined the effect of e-cigarettes on
smoking reduction and cessation. 29 Forty regular smokers
(unwilling to quit) were invited to attend five study visits
(baseline, week 4, week 8, week 12 and week 24) and followup appointments at each visit. Adverse events and participants' opinions and acceptance of the product were also
monitored. Smokers ranged from 18 to 60 years of age,
smoked greater than or equal to 1S factory made cigarettes
per day for at least the past 10 years and were not currently
trying to quit smoking or hoping to do so in the next 30 days.
At the baseline visit, participants were given a free
e-cigarette kit and were instructed on how to use, charge and
activate the e-cigarette. A four-week supply of 7.4 mg nicotine cartridges was also provided, and participants were
trained on how to load them into the e-cigarette atomizer.
Participants were allowed to use the e-cigarette at their own
convenience throughout the day up to a maximum of four
cartridges per day as recommended by the manufacturer.
They were also instructed to complete a four-week study diary to record their use, the number tobacco cigarettes smoked
and any adverse events. Subjects were invited to subsequent
visits to receive more free supplies of cartridges and study
diaries, to record their exhaled carbon monoxide (eCO) levels
and to give back completed study diaries and unused products. At the final follow-up visit, participants reported product usage (cartridges/day), number of tobacco cigarettes,
and eCO levels and rated the degree of usefulness of the
product.
The product ratings of satisfaction, helpfulness in keeping
them from smoking and whether they would recommend to
a friend who wants to quit or reduce smoking were measured using a visual analogue scale (0 = completely unsatisfied, 10 = fully satisfied). Patients who spontaneously asked
for assistance in quitting were provided with smoking cessation services but were excluded from the study. The majority
(67.So/o) of participants were able to adhere to the program
and returned for the final follow-up visit with an overall quit
rate of 22.S percent. There was at least a SO percent reduction in cigarette smoking in 32.S percent of participants.
Overall SS percent of participants exhibited reduction or
smoking cessation.29 The study suggested that the positive
effect of e-cigarettes could have been due to their ability to
replace some of the rituals associated with smoking (e.g.,
hand-to-mouth action of smoking). E-cigarette use was not
found to produce increased CO levels. Serious adverse events
or events causing unscheduled visits to a healthcare provider
did not occur. The most frequent adverse events were mouth
irritation (20.6%), throat irritation (32.4%) and dry cough
(32.4%) possibly due to the low toxicity of propylene glycol.
However, these adverse events subsided with time, and participants were satisfied with the product. Side effects such as
depression, anxiety, insomnia, irritability, hunger and constipation that are normally present in smoking cessation trials
with drugs for nicotine dependence were absent.
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The authors admitted that the study was small and uncontrolled; therefore, the results could have been due to chance
and should be interpreted with caution.29 Additionally, the
study's design should not be considered as an ordinary cessation study because the design included smokers who were
unwilling to quit and used e-cigarettes. Based on this study,
e-cigarettes should not be compared to other smoking cessation products, and the absence of withdrawal symptoms and
adverse effects should be considered with caution, given that
the authors did not study these variables rigorously.
Conclusion from Selected Studies on Electronic Cigarettes
These five studies demonstrate that the use of e-cigarettes is
not yet safe and healthy for the public.25-29 There are still
many factors including toxicity and efficacy in smoking cessation that need to be studied further. An article by Simon
Chapman, professor of public health at the University of Sydney, stresses many mistakes have been made with the way
tobacco has been sold and marketed.23 In order to avoid the
same mistakes with e-cigarettes, early caution should be taken. Chapman suggests scheduling e-cigarettes and creating
access through pharmacies with a permit or prescription as a
way for them to be overseen for quality and safety. This
tighter control would allow e-cigarettes to be carefully monitored through research, and their availability to be relaxed or
tightened as evidence of benefits and/or harms develop.
Clinical Applications and the Role of the Pharmacist
As of now the FDA has not completely studied and evaluated
e-cigarettes and cannot state if there is any therapeutic benefit from the use of these products. Currently, only e-cigarettes
that are marketed for or claim a therapeutic purpose such as
smoking cessation are being regulated.30 The FDA issued a
proposition that would allow the agency's tobacco authority
to cover additional products that meet the legal definition of
a tobacco product, such as e-cigarettes and any other products containing tobacco derivatives such as nicotine.30,19
Before initiating any form of smoking cessation, pharmacists
should consider using the "SAs" approach. This involves
asking the patient about his or her current tobacco use,
advising them on the importance of quitting and the
health benefits that come with smoking cessation, and
assessing if the patient is willing and ready to quit. Once
the patient is ready, the pharmacist should assist the patient
in selecting and beginning smoking cessation therapy and
arranging follow-up sessions to help monitor and encourage the patient's progress. A first-line treatment to smoking
cessation for most patients is nicotine replacement therapy
(NRT).31 Other first-line treatments include prescription
products such as varenicline and bupropion SR. On the market, there are a number of NRT products designed to help
patients end their need for nicotine. Available NRT products
include gums, lozenges, nasal sprays, inhalers and patches.
Each of these products have advantages and disadvantages
which the patient should discuss with a pharmacist in order
to determine which product is right for them.3 2 As of now, ecigarettes have not been formally classified as a NRT product, but there is continuing research to determine if
e-cigarettes would qualify.19
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From the presented studies and evidence, the use of
e-cigarettes can be toxic to the health of patients, and without regulation to standardize e-cigarettes, it may be difficult
to discern which products are safe.Jo Although, there are no
official counseling guidelines for e-cigarettes, it is still important that pharmacists use available knowledge to inform
patients on the effects of e-cigarettes. Most e-cigarettes do
not contain a tamper resistant mechanism, which has resulted in children overdosing on nicotine by consuming the concentrated nicotine liquid. Likewise, various liquids cause
damage to cells, and certain e-cigarette devices, especially
ones that are higher in voltage, can contribute additional
harm.2s In comparison to traditional tobacco based cigarettes, it is not accurate to say that e-cigarettes are better or
worse. This is because e-cigarettes are not being formally
regulated in the same way.19 Patients who are looking to
switch from traditional tobacco cigarettes to e-cigarettes as a
form of NRT should be informed about the consequences of
using e-cigarettes and their effects on health; an example
being that certain nicotine liquids and e-cigarettes can cause
more cytotoxicity when compared to other brands of
e-cigarettes.27,30,32 If a patient wants to quit smoking cigarettes, pharmacists should make recommendations on safer
established methods, such as NRT products, before suggesting e-cigarettes. Patients already using e-cigarettes as a form
of smoking cessation should be encouraged to switch to established methods or, at a minimum, invest in products that
progressively contain less and less nicotine, eventually seceding from all nicotine and tobacco containing products.25,30,31 Utilizing the above counseling points, regulated
forms of NRT, or referral to a physician who can prescribe a
prescription based smoking cessation therapy, would all be
safer options than using an e-cigarette.27,30

Conclusion
Presently, there have been studies to show that certain
e-cigarette and nicotine liquid brands are safer than the
traditional e-cigarette, but that does not mean e-cigarettes in
general are completely safe. The FDA has listed a number of
adverse effects that have been attributed to the chronic use
of e-c;igarettes including, but not limited to, chronic heart
failure, pneumonia and seizures. Additional studies, the creation of standards and regulating e-cigarettes like tobacco are
important next steps. Unfortunately, the FDA has not instituted such regulations but is currently working on extending
the e-cigarette classification to be in the same category as
traditional tobacco products. If a standard and safe
e-cigarette is created, this could add another potentially safer
NRT option for smoking cessation.
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